Premium
Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase
Author(s) -
Millot Frédéric,
Claviez Alexander,
Leverger Guy,
Corbaciglu Selim,
Groll Andreas H.,
Suttorp Meinolf
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24521
Subject(s) - medicine , imatinib , myeloid leukemia , blood cancer , imatinib mesylate , leukemia , oncology , cancer , pediatrics
Imatinib can be safely discontinued in adults with chronic myeloid leukemia (CML) where there is a prolonged complete molecular response (CMR). No data are available in the pediatric population. Six children with CML discontinued imatinib by themselves. Only three of them were in CMR but for <2 years. A significant increase in transcript level was observed in all six patients after cessation of imatinib and five patients lost the major molecular response (MMR). Four patients regained the MMR within 3 months. Cessation of imatinib in children is not recommended outside a trial, particularly in patients without prolonged CMR. Pediatr Blood Cancer 2014;61:355–357. © 2013 Wiley Periodicals, Inc.